Lifeboat Foundation

Imagine being able to know when a stock is heading up or going down in the next week and then with the remaining cash you have, you would put all of your money to invest or short that stock. After playing the stock market with the knowledge of whether or not the stock will increase or decrease in value, you might end up a millionaire!

Unfortunately, this is impossible because no one can know the future. However, we can make estimated guesses and informed forecasts based on the information we have in the present and the past regarding any stock. An estimated guess from past movements and patterns in stock price is called Technical Analysis. We can use Technical Analysis (TA)to predict a stock’s price direction, however, this is not 100% accurate. In fact, some traders criticize TA and have said that it is just as effective in predicting the future as Astrology. But there are other traders out there who swear by it and have established long successful trading careers.

In our case, the Neural Network we will be using will utilize TA to help it make informed predictions. The specific Neural Network we will implement is called a Recurrent Neural Network — LSTM. Previously we utilized an RNN to predict Bitcoin prices (see article below):

GRAND FORKS, N.D. — Many students celebrate completing their Ph.D. with a party. I, ever the space nerd, climbed into a spacesuit instead.

I spent seven years studying remotely at the University of North Dakota (UND) here, which is home to a variety of space-related facilities. I studied crews at the Inflatable Lunar/Mars Habitat — a facility where groups of three or four people live as astronauts for a week or two, including venturing outside in pressurized spacesuits.

Some big M&A is afoot in Israel in the world of smart transportation. According to multiple reports and sources that have contacted TechCrunch, chip giant Intel is in the final stages of a deal to acquire Moovit, a startup that applies AI and big data analytics to track traffic and provide transit recommendations to some 800 million people globally. The deal is expected to close in the coming days at a price believed to be in the region of $1 billion.

We have contacted Nir Erez, the founder and CEO of Moovit, as well as Intel spokespeople for a comment on the reports and will update this story as we learn more. For now, Moovit’s spokesperson has not denied the reports and what we have been told directly.

“At this time we have no comment, but if anything changes I’ll definitely let you know,” Moovit’s spokesperson.

https://youtube.com/watch?v=zTpYDP7FUnc

Ladies Monday with Brittany Pettibone.

All Guest Author Posts are submitted or additional content Chronicle has added to the website. To be a Guest Author please visit our “Post Your Article” page.

Continue reading “Media Calls For Hardcore Internet Censorship” »

UV light kills viruses in air-borne droplets and of the three types of ultraviolet light – UV-A, UV-B and UV-C – UV-C is the most damaging.

UV-C can damage the nucleic acids within an organism and prevent it from replicating. Its use as a disinfectant is fairly common in hospital and laboratory settings.

In Israel, IAI engineers have been working on a system that can work autonomously and automatically in a plane, once given a plan of the aircraft or any other large space.

HOUSTON, May 1, 2020 — Rice University researchers plan to reconfigure their wastewater-treatment technology to capture and deactivate the virus that causes COVID-19. Their chemical-free nanotechnology, introduced earlier this year as a way to kill bacterial “superbugs” and degrade their antibiotic resistance genes in wastewater, will use graphitic carbon nitride to selectively adsorb viruses and then disable them by activating nearby catalysts with light. The team believes that this photocatalytic approach to disinfection — what it calls the “trap-and-zap” treatment approach — could be used to recognize coronaviruses that cause not only COVID-19 but also MERS and SARS.

An injectable antibiotic developed by a team at The Hebrew University of Jerusalem could have a deep impact not only on treating COVID-19 patients, but also on all those affected by antibiotic-resistant infections.

Prof. Yechezkel Barenholz and Dr. Ahuva Cern with their team at the Laboratory of Membrane and Liposome Research at Hadassah-University Medical Center in Jerusalem have been working on improving the performance of drugs in treating different illnesses, including cancer and infectious diseases, for many years. Their method is based on encapsulating the drugs in particles that can be injected into the body.

“We take well-known and established drugs and encapsulate them in two types of particles, called ‘liposomes’ because they are made of lipids, meaning fats,” Barenholz told The Jerusalem Post. “These particles imitate the human cell because they feature a membrane separating the outer world and the inner world of the unit.”

Continue reading “Israeli team finds way to inject drug against COVID-19-related infections” »

The debate is focused on a subset of gain-of-function studies that manipulate deadly viruses to increase their transmissibility or virulence. “This is what happens to viruses in the wild”, explains Carrie Wolinetz, head of the NIH Office of Science Policy. “Gain-of-function experiments allow us to understand how pandemic viruses evolve, so that we can make predictions, develop countermeasures, and do disease surveillance”. Although none of the widely publicised mishaps of 2014 involved such work, the NIH decided to suspend funding for gain-of-function studies involving influenza, MERS-CoV, and SARS-CoV.

The US moratorium on gain-of-function experiments has been rescinded, but scientists are split over the benefits—and risks—of such studies. Talha Burki reports.

On Dec 19, 2017, the US National Institutes of Health (NIH) announced that they would resume funding gain-of-function experiments involving influenza, Middle East respiratory syndrome coronavirus, and severe acute respiratory syndrome coronavirus. A moratorium had been in place since October, 2014. At the time, the NIH had stated that the moratorium “will be effective until a robust and broad deliberative process is completed that results in the adoption of a new US Government gain-of-function research policy”. This process has now concluded. It was spearheaded by the National Science Advisory Board for Biosecurity (NSABB) and led to the development of a new framework for assessing funding decisions for research involving pathogens with enhanced pandemic potential. The release of the framework by the Department of Health and Human Services (HHS), of which NIH is part, signalled the end of the funding pause.

Continue reading “Ban on gain-of-function studies ends” »

Circa 2015

Half the world is facing water shortages, so is it time for us all to start drinking recycled sewage?